An inhaled version of miRagen Therapeutics‘ potential fibrosis therapy MRG-201 rendered genes involved in scarring nearly inactive in a rat…
Articles by Magdalena Kegel
Synairgen and Pharmaxis are preparing a Phase 1 clinical trial of PXS-5382A for pulmonary fibrosis and other tissue-scarring disorders. Positive…
miRagen Therapeutics will release preclinical data supporting an inhaled version of its investigational treatment MRG-201 for idiopathic pulmonary fibrosis (IPF)…
Researchers at New York’s Columbia University have developed a new way of restoring lung function by replacing airway surface…
The influence of smoking on the course of idiopathic pulmonary fibrosis (IPF) is complex, and a recent study did not…
GLPG1690, an investigational therapy developed by Galapagos to treat idiopathic pulmonary fibrosis (IPF), prevented further lung decline in a Phase 2a trial,…
Physical activity predicts mortality in idiopathic pulmonary fibrosis (IPF) as well as established measures, according to a study that suggests…
Ofev (nintedanib) can counter lung fibrosis by correcting abnormalities in lung blood-vessel structure, according to a German study in mice. The…
Esbriet (pirfenidone) and Ofev (nintedanib) remain the most reliably effective treatments for idiopathic pulmonary fibrosis (IPF), according to…
Researchers from two Southern U.S. universities and a federal healthcare agency have begun a study of pulmonary fibrosis in people…